BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 17290058)

  • 1. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.
    Rizk NP; Venkatraman E; Bains MS; Park B; Flores R; Tang L; Ilson DH; Minsky BD; Rusch VW;
    J Clin Oncol; 2007 Feb; 25(5):507-12. PubMed ID: 17290058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
    Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
    Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system.
    Rizk N; Venkatraman E; Park B; Flores R; Bains MS; Rusch V;
    J Thorac Cardiovasc Surg; 2006 Dec; 132(6):1374-81. PubMed ID: 17140960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
    Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
    Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status.
    Kim MP; Correa AM; Lee J; Rice DC; Roth JA; Mehran RJ; Walsh GL; Ajani JA; Maru DM; Chang JY; Marom EM; Macapinlac HA; Lee JH; Vaporciyan AA; Rice T; Swisher SG; Hofstetter WL
    Ann Thorac Surg; 2010 Sep; 90(3):884-90; discussion 890-1. PubMed ID: 20732513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proposed modification of nodal status in AJCC esophageal cancer staging system.
    Hofstetter W; Correa AM; Bekele N; Ajani JA; Phan A; Komaki RR; Liao Z; Maru D; Wu TT; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Francis A; Blackmon S; Swisher SG
    Ann Thorac Surg; 2007 Aug; 84(2):365-73; discussion 374-5. PubMed ID: 17643602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic prognostic factors in Barrett's associated adenocarcinoma: a follow-up study of 96 patients.
    Torres C; Turner JR; Wang HH; Richards W; Sugarbaker D; Shahsafaei A; Odze RD
    Cancer; 1999 Feb; 85(3):520-8. PubMed ID: 10091725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of long-term survival after resection of esophageal carcinoma with nonregional nodal metastases.
    Lee PC; Port JL; Paul S; Stiles BM; Altorki NK
    Ann Thorac Surg; 2009 Jul; 88(1):186-92; discussion 192-3. PubMed ID: 19559222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: prognostic value of circumferential resection margin and stratification of N1 category.
    Saha AK; Sutton C; Rotimi O; Dexter S; Sue-Ling H; Sarela AI
    Ann Surg Oncol; 2009 May; 16(5):1364-70. PubMed ID: 19252949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
    Meredith KL; Weber JM; Turaga KK; Siegel EM; McLoughlin J; Hoffe S; Marcovalerio M; Shah N; Kelley S; Karl R
    Ann Surg Oncol; 2010 Apr; 17(4):1159-67. PubMed ID: 20140529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation.
    Gu Y; Swisher SG; Ajani JA; Correa AM; Hofstetter WL; Liao Z; Komaki RR; Rashid A; Hamilton SR; Wu TT
    Cancer; 2006 Mar; 106(5):1017-25. PubMed ID: 16456809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma.
    Rizzetto C; DeMeester SR; Hagen JA; Peyre CG; Lipham JC; DeMeester TR
    J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1228-36. PubMed ID: 18544359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus.
    Rohatgi PR; Swisher SG; Correa AM; Wu TT; Liao Z; Komaki R; Walsh G; Vaporciyan A; Lynch PM; Rice DC; Roth JA; Ajani JA
    Cancer; 2005 Oct; 104(7):1349-55. PubMed ID: 16130133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the N1c category of the new American Joint Committee on cancer staging system applicable to patients with rectal cancer who receive preoperative chemoradiotherapy?
    Song JS; Chang HJ; Kim DY; Kim SY; Baek JY; Park JW; Park SC; Choi HS; Oh JH
    Cancer; 2011 Sep; 117(17):3917-24. PubMed ID: 21858800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival in lymph node negative adenocarcinoma of the esophagus after R0 resection with and without neoadjuvant therapy: evidence for downstaging of N status.
    Leers JM; Ayazi S; Hagen JA; Terterov S; Klipfel N; Oezcelik A; Abate E; Lipham JC; DeMeester SR; Banki F; DeMeester TR
    J Am Coll Surg; 2009 Apr; 208(4):553-6. PubMed ID: 19476789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followed by surgery or surgery alone.
    Kesler KA; Helft PR; Werner EA; Jain NP; Brooks JA; DeWitt JM; Leblanc JK; Fineberg NS; Einhorn LH; Brown JW
    Ann Thorac Surg; 2005 Apr; 79(4):1116-21. PubMed ID: 15797035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response.
    Rohatgi P; Swisher SG; Correa AM; Wu TT; Liao Z; Komaki R; Walsh GL; Vaporciyan AA; Rice DC; Roth JA; Ajani JA
    Cancer; 2005 Dec; 104(11):2365-72. PubMed ID: 16245310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.
    Tong DK; Law S; Kwong DL; Chan KW; Lam AK; Wong KH
    Ann Surg Oncol; 2010 Aug; 17(8):2184-92. PubMed ID: 20217248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcome and recursive partitioning analysis-based prognostic factors in patients with esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy.
    Kim MK; Kim SB; Ahn JH; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HY; Shin JH; Cho KJ; Ryu JS; Park SI
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):725-34. PubMed ID: 18164836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical analysis of 108 cases with adenocarcinoma Barretts's esophagus].
    Han JQ; Liu Q; Liang RX; Qu FS; Yan TX; Sun YH; Li XQ
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):470-3. PubMed ID: 17974287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.